Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05432466 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome
A Phase 3 study of Vascular Ehlers-Danlos Syndrome, sponsored by Acer Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05432466: Recruiting Phase 3 study of Vascular Ehlers-Danlos Syndrome, sponsored by Acer Therapeutics.
NCT05432466 is a Phase 3 study of Vascular Ehlers-Danlos Syndrome that is actively recruiting participants, run by Acer Therapeutics. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05432466, a Phase 3 study of Vascular Ehlers-Danlos Syndrome, is actively recruiting participants, sponsored by Acer Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.
Conditions Studied
Interventions
- DRUG Placebo BID
- DRUG ACER-002 (celiprolol) 200 mg BID
Study Locations (1)
California
- Science 37 - Culver City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2029-04-01 |
| Phase | Phase 3 |
What NCT05432466 shows while recruiting
NCT05432466 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Vascular Ehlers-Danlos Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo BID is the first listed.
NCT05432466 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05432466 about?
NCT05432466 is a clinical study titled "Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome". This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.
What is the current status of trial NCT05432466?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2022-11-07. Estimated completion is 2029-04-01.
What conditions does trial NCT05432466 study?
This clinical trial studies the following conditions: Vascular Ehlers-Danlos Syndrome.
What interventions are being tested in trial NCT05432466?
The interventions under investigation include: Placebo BID (DRUG), ACER-002 (celiprolol) 200 mg BID (DRUG).
Who is sponsoring clinical trial NCT05432466?
This trial is sponsored by Acer Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05432466 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vascular Ehlers-Danlos Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05432466's enrollment target sits among peer trials
150 1520th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI